Eugene Goykhman, MD
Critical Care Medicine · Schenectady, NYNPI 1346381720
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by GSK at 33.9% of the total. Among critical care medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $17.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$775
- AbbVie$364
- Novartis$301
- Genentech USA, Inc.$171
- Johnson & Johnson$164
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,072100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 110 | $1,721 |
| AstraZeneca | 44 | $775 |
| AbbVie | 17 | $364 |
| Novartis | 15 | $301 |
| Genentech USA, Inc. | 13 | $171 |
| Johnson & Johnson | 10 | $164 |
| Insmed, Inc. | 9 | $159 |
| Merck | 8 | $150 |
| Baxter Healthcare | 7 | $140 |
| Boehringer Ingelheim | 6 | $129 |
| Electromed, Inc. | 4 | $114 |
| Amgen | 5 | $112 |
| Jazz Pharmaceuticals Inc. | 5 | $107 |
| Grifols USA, LLC | 4 | $100 |
| Sanofi | 4 | $98 |
| Harmony Biosciences LLC | 3 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $79 |
| Mylan Specialty L.p. | 3 | $56 |
| Pfizer | 2 | $38 |
| Shire North American Group Inc | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $35 |
| Verona Pharma, Inc. | 1 | $29 |
| Gilead | 2 | $23 |
| Philips North America LLC | 1 | $22 |
| Sunovion Pharmaceuticals Inc. | 2 | $19 |
| United Therapeutics Corporation | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $18 |
| Circassia Inc. | 1 | $11 |
How this compares
$5,072 in reported general payments places this provider in the 90th percentile of 442 critical care medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 725 | $1,043,931 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 21 | $236,167 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 100 | $145,866 |
| Breo ElliptaFluticasone/Vilanterol | 127 | $97,117 |
| NucalaMepolizumab | 19 | $88,510 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 40 | $36,817 |
| SymbicortBudesonide/Formoterol Fumarate | 65 | $27,454 |
| Incruse ElliptaUmeclidinium Bromide | 34 | $21,365 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 59 | $20,968 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 462 | $20,168 |
| Spiriva RespimatTiotropium Bromide | 19 | $16,868 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 22 | $7,855 |
| DuleraMometasone/Formoterol | 22 | $7,325 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $6,571 |
| BreynaBudesonide/Formoterol Fumarate | 15 | $4,895 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta | $1,721 | $1,287,739945 claims |
| Grifols USA, LLCProlastin C | $100 | $236,16721 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $775 | $173,320165 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $129 | $23,44032 claims |
| MerckDulera | $150 | $7,32522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 442 critical care medicine providers in New York.
Other critical care medicine in Schenectady
- Joshua RosenbergBrooklyn$881K
- Peter DicpinigaitisBronx$241K
- Roxana SulicaNew York$211K
- Boris ShkolnikAlbany$209K
- Paul StrachanMelville$169K
- Anna PodolanczukNew York$116K
- Joanne HessneyRochester$76K
- Jan BakkerNew York$49K
- Hugh CassiereManhasset$49K
- Robert SladenNew York$40K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.